[1]韩阅, 贾建平, 周爱红. 初次发病的腔隙性脑梗死患者的认知变化特点[J]. 首都医科大学学报, 2010, 31(2): 154-159.
[2]何冰怡, 林阳,秦莲花,等. 腔隙性脑梗死与颅内动脉钙化关系的研究进展[J]. 实用临床医药杂志, 2025, 29 (21): 138-143.
[3]米涛免, 孙永馨. 脑小血管病多样化临床表现的影像学基础[J]. 首都医科大学学报, 2013, 34(6): 860-867.
[4]Del Toro-Pérez C, Guevara-Sánchez E, Martínez-Sánchez P. Treatment of Vascular Parkinsonism: a systematic review[J]. Brain Sci. 2023;13(3):489.
[5]叶益超, 玉石, 佘亚军, 等. 血管性帕金森综合征的研究进展[J]. 中国卒中杂志, 2022, 17(4): 346-350.
[6]钟迪, 张舒婷, 吴波. 《中国急性缺血性脑卒中诊治指南2018》解读[J]. 中国现代神经疾病杂志, 2019, 19(11): 897-901.
[7]Zijlmans J C M, Daniel S E, Hughes A J, et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis[J]. Mov Disord, 2004, 19(6): 630-640.
[8]Joutel A, Chabriat H. Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms[J]. Clin Sci, 2017, 131(8): 635-651.
[9]Gupta D, Kuruvilla A. Vascular parkinsonism: what makes it different?[J]. Postgrad Med J, 2011, 87(1034): 829-836.
[10]Benjamin P, Lawrence A J, Lambert C, et al. Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease[J]. Neuroimage Clin, 2014, 4: 828-837.
[11]Bloem B R, Okun M S, Klein C. Parkinson's disease[J]. Lancet, 2021, 397(10291): 2284-2303.
[12]Zhang Z, Wang Y, Wang J, et al. The role of peripheral inflammation-related biomarkers in distinguishing Parkinsons disease[J]. Parkinsonism Relat Disord, 2024, 123: 106102.
[13]Kim R, Kim H J, Kim A, et al. Peripheral blood inflammatory markers in early Parkinson's disease[J]. J Clin Neurosci, 2018, 58: 30-33.
[14]Santos-García D, De Deus Fonticoba T, Suárez Castro E, et al. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients[J]. J Neural Transm, 2019, 126(12): 1599-1608.
[15]Akıl E, Bulut A, Kaplan I, et al. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease[J]. Neurol Sci, 2015, 36(3): 423-428.
[16]Hosseini S, Shafiabadi N, Khanzadeh M, et al. Neutrophil to lymphocyte ratio in Parkinson's disease: a systematic review and meta-analysis[J]. BMC Neurol, 2023, 23(1): 333.
[17]Stolzenberg E, Berry D, Yang D, et al. A role for neuronal Alpha-synuclein in gastrointestinal immunity[J]. J Innate Immun, 2017, 9(5): 456-463.
[18]Kim R, Kang N, Byun K, et al. Prognostic significance of peripheral neutrophils and lymphocytes in early untreated Parkinson's disease: an 8-year follow-up study[J]. J Neurol Neurosurg Psychiatry, 2023, 94(12): 1040-1046.
[19]García-Sanz P, M F G Aerts J, Moratalla R. The role of cholesterol in α-synuclein and Lewy body pathology in GBA1 Parkinson's disease[J]. Mov Disord, 2021, 36(5): 1070-1085.
[20]Jiang Z, Xu X R, Gu X J, et al. Effects of higher serum lipid levels on the risk of Parkinson's disease: a systematic review and meta-analysis[J]. Front Neurol, 2020, 11: 597.
[21]Fu X X, Wang Y, He X F, et al. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease[J]. Lipids Health Dis, 2020, 19(1): 97.
[22]Fang F, Zhan Y Q, Hammar N, et al. Lipids, apolipoproteins, and the risk of Parkinson disease: a prospective cohort study and a mendelian randomization analysis[J]. Circ Res, 2019, 125(6): 643-652.
[23]Nam G E, Kim S M, Han K, et al. Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study[J]. PLoS Med, 2018, 15(8): e1002640.
[24]Roh J H, Lee S, Yoon J H. Metabolic syndrome and Parkinson's disease incidence: a nationwide study using propensity score matching[J]. Metab Syndr Relat Disord, 2021, 19(1): 1-7.
[25]Park J H, Lee C W, Nam M J, et al. Association of high-density lipoprotein cholesterol variability and the risk of developing Parkinson disease[J]. Neurology, 2021, 96(10): e1391-e1401.
[26]Hong X, Guo W T, Li S S. Lower blood lipid level is associated with the occurrence of Parkinson's disease: a meta-analysis and systematic review[J]. Int J Clin Pract, 2022, 2022: 9773038.
[27]Sterling N W, Lichtenstein M, Lee E Y, et al. Higher plasma LDL-cholesterol is associated with preserved executive and fine motor functions in Parkinson's disease[J]. Aging Dis, 2016, 7(3): 237-245.
[28]陈彤, 王鲁宁, 王振福, 等. 低密度脂蛋白胆固醇水平与帕金森病的关系[J]. 解放军保健医学杂志, 2008, 10(1): 11-13.
[29]Reider-Groswasser I, Bornstein N M, Korczyn A D. Parkinsonism in patients with lucanar infarcts of the basal ganglia[J]. Eur Neurol, 1995, 35(1): 46-49.
[30]Jellinger K A. Vascular parkinsonism: an update[J]. J Neural Transm, 2025, 132(7): 899-919.
[31]Dunet V, Deverdun J, Charroud C, et al. Cognitive impairment and basal ganglia functional connectivity in vascular parkinsonism[J]. AJNR Am J Neuroradiol, 2016, 37(12): 2310-2316.
|